FrancophonIA/ELRC3.0 huggingface dataset:
English: Comfortis 1040 mg chewable tablets for dogs
Maltese: Comfortis 180 mg pilloli li jintmagħdu għal klieb u qtates
English: The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
Maltese: Il-konsistenza ta' din iċ-ċifra fi studji farmakokinetiċi u studji oħra jindika komparabilità fl-assorbiment, il-metaboliżmu u leliminazzjoni taż-żewġ spinosyns ewlenin.
English: 5.2 Pharmacokinetic particulars
Maltese: KWALITAJIET FARMAKOLOĠIĊI
English: This activity persists for up to 4 weeks after a single administration of the product.
Maltese: Din l-attività tippersisti għal sa 4 ġimgħat wara li lprodott ikun ingħata darba biss.
English: However there was no evidence in the clinical observations and clinical chemistry parameters that indicated any loss in organ function.
Maltese: Madankollu, ma kien hemm evidenza fl-osservazzjonijiet kliniċi u l-parametri kimiċi kliniċi li kienu jindikaw xi telf tal-funzjoni tal-organi.
English: Comfortis 90 mg chewable tablets for dogs and cats Comfortis 140 mg chewable tablets for dogs and cats Comfortis 180 mg chewable tablets for dogs and cats Comfortis 270 mg chewable tablets for dogs and cats Comfortis 425 mg chewable tablets for dogs and cats Comfortis 665 mg chewable tablets for dogs Comfortis 1040 mg chewable tablets for dogs Comfortis 1620 mg chewable tablets for dogs
Maltese: Comfortis 270 mg pilloli li jintmagħadu għal klieb u qtates Comfortis 425 mg pilloli li jintmagħadu għal klieb u qtates Comfortis 665 mg pilloli li jintmagħadu għal klieb Comfortis 1040 mg pilloli li jintmagħadu għal klieb Comfortis 1620 mg pilloli li jintmagħadu għal klieb
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE
Maltese: Prekawzjonijiet Speċjali għall-Użu
English: Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea.
Maltese: L-attività insettiċida ta' spinosad hi kkaratterizzata b'eċitazzjoni fin-nervi li twassal għal kontrazzjonijiet muskolari u rogħda,
English: Children should not come into contact with the veterinary medicinal product.
Maltese: Staqsi lill-veterinarju tiegħek dwar kif l-aħjar li tarmi l-mediċini li ma jkunux aktar meħtieġa.
English: The full EPAR and risk management plan summary for Xadago can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The active substance in Xadago, safinamide, is a ‘monoamine oxidase-B (MAO-B) inhibitor'.
Maltese: Is-sustanza attiva fi Xadago, safinamide, hija ”inibitur tal-monoamine oxidase-B (MAO-B)”.
English: Xadago contains the active substance safinamide.
Maltese: Xadago fih is-sustanza attiva safinamide.
English: This is a summary of the European public assessment report (EPAR) for Xadago.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Xadago.
English: The most common side effects with Xadago (which may affect up to 1 in 10 people) are insomnia (difficulty sleeping), dyskinesia (difficulty controlling movement), somnolence (sleepiness), dizziness, headache, worsening of existing Parkinson's disease, cataract (clouding of the lens), orthostatic hypotension (drop in blood pressure when standing up), nausea (feeling sick) and falls.
Maltese: L-effetti sekondarji l-aktar komuni b'Xadago (li jistgħu jaffettwaw aktar minn 1 minn kull 10) huma insomnija (diffikulta' fl-irqad), diskinesija (diffikulta' fil-kontroll tal-movimenti), sonnolenza (ngħas), sturdament, uġigħ ta' ras, iggravar tal-marda ta' Parkinson eżistenti, katarretti (lenti mċajpra), pressjoni orostatika baxxa (tnaqqis fil-pressjoni meta toqgħod bilwieqfa), nawsja (tħossok ma tiflaħx) u waqgħat.
English: Xadago is available as tablets (50 and 100 mg) and can only be obtained with a prescription.
Maltese: Xadago huwa disponibbli bħala pilloli (50 u 100 mg) u jista' jinkiseb biss b'riċetta ta' tabib.
English: Other information about Xadago
Maltese: Informazzjoni oħra dwar Xadago
English: It blocks the enzyme monoamine oxidase type B (which breaks down dopamine), thereby helping to restore dopamine levels in the brain and improving the patient's symptoms.
Maltese: Timblokka l-enzima monoamine oxidase tip B (li tkisser id-dopamina), u b'hekk tgħin tirrestawra l-livelli taddopamina fil-moħħ u ttejjeb is-sintomi tal-pazjent.
English: Why is Xadago approved?
Maltese: Għaliex ġie approvat Xadago?
English: Xadago, as an add-on treatment to levodopa with or without other medicines for Parkinson's disease, has been compared with placebo (a dummy treatment) in two main studies involving 1,218 patients with late stage Parkinson's disease who experienced fluctuations.
Maltese: Xadago, bħala kura add-on ma' levodopa bi jew mingħajr mediċini oħrajn għall-marda ta' Parkinson, tqabbel ma' plaċebo (kura finta) f'żewġ studji ewlenin li involvew 1,218-il pazjenti bil-marda ta' Parkinson fi stadju avvanzat li esperjenzaw flutwazzjonijiet.
English: It is used in addition to levodopa (a medicine commonly used to treat the symptoms of Parkinson's disease) either alone or in combination with other medicines for Parkinson's, in patients with mid- to late-stage Parkinson's disease who are having ‘motor fluctuations'.
Maltese: Jintuża bħala addizzjoni ma' levodopa (mediċina li tintuża b'mod komuni fil-kura tal-marda ta' Parkinson) jew waħdu jew f'kombinazzjoni ma' mediċini oħrajn għall-Parkinson, f'pazjenti bil-marda ta' Parkinson fl-istadji intermedji sa avvanzati li jkun qed ikollhom ‘flutwazzjonijiet motorji'.
English: Xadago is a medicine used to treat Parkinson's disease, a progressive brain disorder that causes shaking, slow movement and muscular stiffness.
Maltese: Xadago huwa mediċina li tintuża fil-kura tal-marda ta' Parkinson, distrub progressiv tal-moħħ li jikkawża rogħda, moviment bil-mod u għebusija muskolari.
English: The Committee concluded that the effect of Xadago on the daily time that patients lived without motor symptoms was of clinical relevance, also taking into account the response reported in the literature for other Parkinson's medicines.
Maltese: Il-Kumitat ikkonkluda li l-effett ta' Xadago fuq il-ħin ta' kuljum li l-pazjenti għexu mingħajr sintomi motorji kien klinikament relevanti, b'kunsiderazzjoni għar-rispons irrappurtat fil-letteratura għal mediċini talParkinson oħrajn.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Xadago on 24 February 2015.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Xadago fl-24 ta' Frar 2015.
English: In both studies, 6 months treatment with Xadago increased the time during the day during which patients were ‘on' and able to move by 30-60 minutes when compared with placebo.
Maltese: Fiż-żewġ studji, kura għal 6 xhur b'Xadago żiedet iż-żmien matul il-ġurnata li fih il-pazjenti kienu ‘on' u kapaċi jiċċaqalqu bi 30-60 minuta meta mqabbel ma' plaċebo.
English: In patients with Parkinson's disease, certain cells in the brain that produce dopamine die, and as dopamine is involved in controlling movement, the patient's movement worsens over time.
Maltese: F'pazjenti bil-marda ta' Parkinson, ċerti ċelloli fil-moħħ li jipproduċu d-dopamina jmutu, u peress li ddopamina hija involuta fil-kontroll tal-moviment, il-moviment tal-pazjent jiggrava maż-żmien.
English: What are the risks associated with Xadago?
Maltese: X'inhuma r-riskji assoċjati ma' Xadago?
English: Treatment should be started at a dose of 50 mg a day and the doctor may increase the dose up to 100 mg a day based on patient's need.
Maltese: Il-kura għandha tinbeda b'doża ta' 50 mg kuljum u t-tabib jista' jżid id-doża sa 100 mg kuljum abbażi talbżonn tal-pazjent.
English: How does Xadago work?
Maltese: Kif jintuża Xadago?
English: Xadago was also investigated as an add-on to treatment in 2 studies in patients with early Parkinson's disease without fluctuations, but these studies did not show a clear benefit and the company did not pursue this use as part of the application.
Maltese: Xadago ġie investigat ukoll bħala kura add-on f'2 studji f'pazjenti bil-marda ta' Parkinson bikrija mingħajr flutwazzjonijiet, iżda dawn l-istudji ma wrewx benefiċċju ċar u l-kumpanija ma segwietx dan l-użu bħala parti mill-applikazzjoni.
English: Further information on SevoFlo can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The most common side effects with SevoFlo, which may affect more than 1 in 10 animals, are low blood pressure, rapid breathing, muscle tenseness, excitation, a temporary inability to breathe, small muscle twitches and vomiting.
Maltese: L-effetti sekondarji l-aktar komuni b'SevoFlo, li jistgħu jaffettwaw aktar minn annimal 1 minn kull 10, huma pressjoni tad-demm baxxa, teħid tan-nifs aktar mgħaġġel, twebbis tal-muskoli, eċitazzjoni, nuqqas temporanju fit-teħid tan-nifs, ġbid żgħir fil-muskoli, u remettar.
English: Studies in dogs found that SevoFlo was as effective at starting and maintaining anaesthesia as other anaesthetic agents, such as isoflurane (another anaesthetic gas), thiopental, propofol, and ketamine plus diazepam.
Maltese: Studji fuq klieb sabu li SevoFlo kien effettiv fit-tnedija u fil-manutenzjoni tal-anestesija daqs aġenti anestetiċi oħra, bħall-isofluran (gass anestetiku ieħor), it-tijopental, il-propofol, u l-ketamina flimkien ma' diażepam.
English: What are the risks associated with SevoFlo?
Maltese: X'inhuma r-riskji assoċjati ma' SevoFlo?
English: It contains the active substance sevoflurane, a chemical which is a liquid at room temperature, but when heated becomes a gas (vaporises).
Maltese: Fih is-sustanza attiva sevofluran, kimika likwida f'temperatura ambjentali, imma li meta tissaħħan issir gass (tivvaporizza).
English: This is a rare life-threatening condition usually triggered by exposure to certain general anaesthetics that is associated with muscle spasm and very high body temperatures.
Maltese: Din hija marda rari li hija theddida għall-ħajja li normalment titqanqal minn esponiment għal ċerti anestetiċi ġenerali u hija assoċjata ma' spażmi muskolari u temperaturi tal-ġisem għoljin ħafna.
English: Sevoflurane mimics the action of GABA, a substance that naturally reduces brain activity, and blocks the action of glutamate, which stimulates the activity of the brain.
Maltese: Is-sevofluran timita l-azzjoni ta' GABA, sustanza li tnaqqas l-attività tal-moħħ b'mod naturali, u timblokka l-azzjoni ta' glutamat, li tistimula lattività tal-moħħ.
English: SevoFlo is a general anaesthetic for dogs and cats.
Maltese: SevoFlo huwa anestetiku ġenerali għall-klieb u l-qtates.
English: For cats, a review of published scientific literature showed that SevoFlo is effective for anaesthesia and that it is compatible with a range of sedative and pain-relieving medicines used in anaesthesia.
Maltese: Għall-qtates, rieżami tal-litteratura xjentifika ppubblikata wera li SevoFlo huwa effettiv għall-anestesija u li huwa kompatibbli ma' firxa ta' mediċini sedattivi u li jtaffu l-uġigħ li jintużaw fl-anestesija.
English: The effectiveness of SevoFlo was comparable to isoflurane.
Maltese: effikaċja ta' SevoFlo kienet komparabbli ma' isofluran.
English: Other information about SevoFlo
Maltese: Kif jintuża SevoFlo?
English: SevoFlo produced a relatively rapid and smooth start of anaesthesia in dogs, followed by a good recovery.
Maltese: SevoFlo pproduċa induzzjoni anestetika relattivament rapida u bla intoppi fil-klieb, segwita b'irkupru tajjeb.
English: In addition, SevoFlo has been commonly used off-label (use that is not officially authorised) as an anaesthetic for cats for more than 10 years and therefore its use in cats is considered to be ‘well-established'.
Maltese: Barra minn hekk, SevoFlo intuża ta' spiss mhux skont it-tikketta (użu li mhuwiex awtorizzat uffiċjalment) bħala anestetiku għall-qtates għal aktar minn 10 snin u għaldaqstant l-użu tiegħu fil-qtates huwa meqjus bħala “stabbilit sew”.
English: If a person accidentally inhales sevoflurane vapour, this may cause symptoms such as shivering, nausea, headache, low blood pressure, decreased heart rate and even reduced breathing.
Maltese: Jekk persuna aċċidentalment tieħu n-nifs mill-fwar ta' sevofluran, dan jista' jikkawża sintomi bħal tertir, nawżja, uġigħ ta' ras, pressjoni tad-demm baxxa, ritmu iktar baxx tat-taħbit tal-qalb u anke saħansitra tnaqqis fit-teħid tan-nifs.
English: SevoFlo is used to bring about and maintain general anaesthesia (loss of consciousness).
Maltese: SevoFlo jintuża biex jibda kif ukoll biex iżomm l-anestesija ġenerali (telfien tas-sensi).
English: SevoFlo received a marketing authorisation valid throughout the EU for SevoFlo on 11 December
Maltese: Ħarsa ġenerali lejn SevoFlo u għal xiex huwa awtorizzat fl-UE
English: For the full list of side effects of SevoFlo, and for the full list of restrictions, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji ta' SevoFlo, u għal-lista sħiħa tar-restrizzjonijiet, ara l-fuljett ta tagħrif.
English: The European Medicine's Agency decided that SevoFlo's benefits are greater that its risks and it can be authorised for use in the EU.
Maltese: L-Aġenzija Ewropea għall-Mediċini iddeċidiet li l-benefiċċji ta' SevoFlo huma akbar mir-riskji tiegħu u li jista' jiġi awtorizzat għall-użu fl-UE.
English: How does SevoFlo work?
Maltese: Informazzjoni oħra dwar SevoFlo?
English: Penicillin (an antibiotic).
Maltese: • Peniċillin (antibijotiku).
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS Non-Perforated calendar foil (7, 14, 28, 56 and 98 tablets)
Maltese: Strixxa bil-kalendarju mhux imtaqqba (7, 14, 28, 56 u 98 pilloli)
English: Atacand Plus is indicated for the:
Maltese: Atacand Plus huwa indikat:
English: France, Portugal
Maltese: Franza, Il-Portugall
English: Lithium (a medicine for mental health problems).
Maltese: • Lithium (mediċina għal problemi mentali)
English: Photosensitivity
Maltese: Fotosensittivita
English: Austria, Belgium, Cyprus, Czech Republic, Estonia, Germany, Greece, Finland, Hungary, Iceland, Ireland, Luxembourg, The Netherlands, Norway, Slovakia, Slovenia, Spain, Sweden
Maltese: L-Awstrija, Il-Belġju, Ċipru, Ir-Rpubblika Ċeka, L-Estonja, Il-Ġermanja, Il-Greċja, Il-Finlandja L-Ungerija, L-Islanda, L-Irlanda, Il-Lussemburgu, L-Olanda, In-Norveġja, Is-Slovakkja, Is-Slovenja, Spanja, L-Isvezja
English: pentamidine, sparfloxacine, terfenadine, vincamine iv)
Maltese: mizolastin, pentamidine, sparfloxacine, terfinadine, vincamine iv)
English: • Class III antiarrhythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide)
Maltese: • Antiarritmiċi ta' klassi III (eż. amiodarone, sotalol, dofetilide, ibutilide)
English: Pharmaco-therapeutic group: Angiotensin II antagonists + diuretics, ATC code: C09DA06
Maltese: Antagonisti ta' angiotensin II, flimkien ma dijuretiċi, Kodiċi ATC: C09DA06
English: Pituitary hormone (ACTH).
Maltese: • L-ormon pituitary (ACTH)
English: Compounds which have been investigated in clinical pharmacokinetic studies include warfarin, digoxin, oral contraceptives (i.e. ethinylestradiol/levonorgestrel), glibenclamide and nifedipine.
Maltese: Sustanzi li kienu investigati fi studji kliniċi farmakokinetiċi jinkludu warfarin, digoxin, kontraċettivi orali (i.e. ethinylestradiol/levonorgestrel), glibenclamide u nifedipine.
English: The frequencies used in the tables throughout section 4.8 are: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare
Maltese: Il-frekwenzi li jintużaw fil-tabelli tul sezzjoni 4.8 huma: komuni ħafna (≥ 1/10), komuni (≥ 1/100 sa < 1/10), mhux komuni (≥ 1/1,000 sa < 1/100), rari (≥ 1/10,000 sa < 1/1,000) u rari ħafna
English: • Class Ia antiarrhythmics (e.g. quinidine, hydroquinidine, disopyramide)
Maltese: • Antiarritmiċi ta' klassi Ia (eż. quinidine, hydroquinidine, disopyramide)
English: Steroids such as prednisolone.
Maltese: • Sterojdi bħal prednisolone.
English: Respiratory distress (including pneumonitis and pulmonary oedema)
Maltese: Distress respiratorju (inkluż newmonite u edima pulmonary)
English: There were 26.7 events per 1000 patient-years in the candesartan group versus 30.0 events per 1000 patientyears in the control group (relative risk 0.89, 95% CI 0.75 to 1.06, p=0.19).
Maltese: 7 każijiet għal kull 1000 sena tal-pazjenti fil-grupp ta' candesartan versus 30.0 każ għal kull 1000 sena tal-pazjenti fil-grupp ta' kontroll (riskju relattiv 0.89, 95%CI 0.75 sa 1.06, p=0.19).
English: Based on in vitro data, no interaction would be expected to occur in vivo with medicinal products whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4.
Maltese: Ibbażata fuq dejta in vitro, l-ebda interazzjoni ma hija mistennija li sseħħ in vivo b' mediċini li l-metaboliżmu tagħhom huwa dipendenti fuq isoenżimi ta' cytochrome P450 CYP1A2, CYP 2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 jew CYP3A4.
English: The apparent volume of distribution is approximately 0.8 l/kg.
Maltese: Il-volum apparenti ta' distribuzzjoni huwa bejn wieħed u ieħor 0.8 l/kg
English: you are allergic to sulphonamide medicines.
Maltese: • Inti allerġiku għal mediċini sulphonamide.
English: Respiratory infection.
Maltese: • Infezzjoni respiratorja
English: Toxic epidermal necrolysis, cutaneous lupus erythaematosus-like reactions, reactivation of cutaneous lupus erythaematosus
Maltese: Nekroliżi tossika epidermali, reazzjonijiet fil-ġilda bħal lupus erythaematosus, riattivazzjoni fil-ġilda ta' lupus erythaematosus
English: • Others (e.g. bepridil, cisapride, diphemanil, erythromycin iv, halofantrin, ketanserin, mizolastin,
Maltese: • Oħrajn (eż. bepridil, cisapride, diphemanil, erythromycin iv, halofantrin, ketanserin,
English: No data are available.
Maltese: Lebda dejta ma hija disponibbli.
English: Necrotising angiitis (vasculitis, cutaneous vasculitis)
Maltese: Angite nekrotika (vaskulite, vaskulite tal-ġilda)
English: Leukopenia, neutropenia/agranulocytosis, thrombocytopenia, aplastic anaemia, bone marrow depression, haemolytic anaemia
Maltese: Lewkopenija, newtropenija/agranuloċitosi, tromboċitopenija, anemija aplastika, depressjoni tal-mudullun, anemija emolitika
English: The potassium depleting effect of hydrochlorothiazide could be expected to be potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid derivates, steroids, ACTH).
Maltese: l-effett ta' tnaqqis tal-potassium ta' hydrochlorothiazide jista jkun mistenni li jkun imkabbar bi prodotti mediċinali oħra assoċjati ma telf ta' potassium u ipokalimja (eż dijuretiċi kaljuretiċi oħra, lassattivi, amphotericin, carbenoxolone, penicillin G sodium, derivattivi ta' salicylic acid, sterojdi, ACTH)
English: At the doses contained in Atacand Plus, only minimal effects were observed.
Maltese: Bid-dożi li fih Atacand Plus, effetti minimi biss kienu osservati.
English: Hydrochlorothiazide is rapidly absorbed from the gastrointestinal tract with an absolute bioavailability of approximately 70%.
Maltese: Hydrochlorothiazide huwa assorbit malajr mill-mogħdija gastrointestinali b' biodisponnibilta assoluta ta' bejn wieħed u ieħor 70%.
English: The plasma protein binding of hydrochlorothiazide is approximately 60%.
Maltese: Ir-rabta ta' hydrochlorothiazide mal-proteini tal-plażma huwa bejn wieħed u ieħor 60%.
English: Immune system disorders
Maltese: Disturbi fis-sistema immunitarja Rari
English: The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg) once daily on cardiovascular morbidity and mortality were evaluated in a randomised clinical trial with 4,937 elderly patients (aged 70-89 years, 21% aged 80 or above) with mild to moderate hypertension followed for a mean of 3.7 years (Study on COgnition and Prognosis in the Elderly).
Maltese: L-effetti ta' candesartan cilexetil minn 8-16-il mg (doża medja ta' 12-il mg), darba kuljum, fuq ilmorbidità u l-mortalità kardjovaskulari kienu stmati fi prova klinika randomised b'4,937 pazjent anzjan (ta' età minn 70-89 sena; 21% ta' 80 sena jew aktar) bi pressjoni għolja minn ħafifa sa moderata li kienu segwiti għal medja ta' 3.7 snin (Study on COgnition and Prognosis in the Elderly).
English: Thiazide may increase the risk of adverse effects caused by amantadine.
Maltese: Thiazides jistgħu jżidu r-riskju ta' effetti avversi ikkawżati b' amantadine.
English: Gout.
Maltese: Gotta.
English: Cases of photosensitivity reactions have been reported during use of thiazide diuretics (see section 4.8).
Maltese: Każijiet ta' reazzjonijiet ta' fotosensittivit kienu rrapportati waqt l-użu ta' dijuretiċi thiazide (ara sezzjoni 4.8).
English: Exacerbation or activation of systemic lupus erythaematosus has been reported with the use of thiazide diuretics.
Maltese: Taħrix jew attivazzjoni ta' systemic lupus erythaematosus kien rrapportat bl-użu ta' dijuretiċi thiazide.
English: Amphotericin (for the treatment of fungal infections).
Maltese: • Amphotericin (għal kura ta' infezzjonijiet tal-fungu).
English: In patients with mild to moderate renal impairment, Cmax and AUC of candesartan increased during repeated dosing by approximately 50% and 70%, respectively, but the terminal t½ was not altered, compared to patients with normal renal function.
Maltese: F'pazjenti b'indeboliment tal-kliewi minn ħafif sa moderat is- Cmax u l-AUC ta' candesartan żdiedu waqt għoti ta' dożi ripetuti b'madwar 50% u 70%, rispettivament, iżda t-t½ terminali ma nbidlitx, meta mqabbel ma' pazjenti b'funzjoni normali tal-kliewi.
English: Electrolyte imbalance
Maltese: Żbilanċ elektrolitiku
English: Withdrawals from treatment due to adverse events were similar with candesartan cilexetil/hydrochlorothiazide (2.3-3.3%) and placebo (2.7-4.3%).
Maltese: Fi studji kliniċi kkontrollati b' candesartan cilexetil/hydrochlorothiazide reazzjonijiet avversi kienu ħfief u temporanji.It-twaqqif tal-kura minħabba avvenimenti avversi kien jixxiebah b'candesartan cilexetil/hydrochlorothiazide (2.3-3.3%) u bi plaċebo (2.7-4.3%).
English: The terminal t½ of hydrochlorothiazide is approximately 8 hours.
Maltese: It- t½ terminali ta' hydrochlorothiazide huwa ta' bejn wieħed u ieħor 8 sigħat.
English: Atacand Plus and associated names (see Annex I) 8 mg/12.5 mg tablets Atacand Plus and associated names (see Annex I) 16 mg/12.5 mg tablets Atacand Plus and associated names (see Annex I) 32 mg/12.5 mg tablets Atacand Plus and associated names (see Annex I) 32 mg/25 mg tablets
Maltese: Atacand Plus u ismijiet assoċjati (ara Anness I) 8 mg/12.5 mg pilloli Atacand Plus u ismijiet assoċjati (ara Anness I) 16 mg/12.5 mg pilloli Atacand Plus u ismijiet assoċjati (ara Anness I) 32 mg/12.5 mg pilloli Atacand Plus u ismijiet assoċjati (ara Anness I) 32 mg/25 mg pilloli
English: Uncommon Rash, urticaria, photosensitivity reactions
Maltese: Raxx, urtikarja, reazjonijiet ta' fotosensittivita
English: Uncommon Anorexia, loss of appetite, gastric irritation, diarrhoea, constipation
Maltese: Anoressija, nuqqas t aptit, irritazzjoni gastrika, dijarea, stitikezza Pankreatite
English: Muscle spasm
Maltese: Spażmu tal-muskoli
English: Atacand Plus is contraindicated in patients with severe renal impairment (creatinine clearance < 30 ml/min/1.73 m2 BSA) (see section 4.3).
Maltese: Atacand Plus huwa kontraindikat f' pazjenti b'indeboliment tal-kliewi qawwi (tneħħija talkrejatinina < 30 ml/min/ 1.73 m2 l-erja tas-superfiċe tal- ġisem) (ara sezzjoni 4.3)
English: The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.
Maltese: l-effett ipergliċemiku ta' beta-blokers u diazoxide jista jiżdied b' thiazides.
English: [See Annex I - To be completed nationally] candesartan cilexetil/hydrochlorothiazide
Maltese: [Ara Anness I - Biex timtela mill-pajjiż partikolari] candesartan cilexetil/hydrochlorothiazide